Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

SELL
$0.94 - $1.23 $665,670 - $871,036
-708,160 Reduced 74.15%
246,883 $237,000
Q2 2023

Aug 14, 2023

SELL
$1.1 - $1.54 $1.04 Million - $1.46 Million
-949,952 Reduced 49.87%
955,043 $1.16 Million
Q1 2023

May 15, 2023

BUY
$1.19 - $2.09 $257,704 - $452,606
216,558 Added 12.83%
1,904,995 $2.4 Million
Q4 2022

Feb 14, 2023

BUY
$1.67 - $2.35 $2.51 Million - $3.54 Million
1,504,714 Added 819.01%
1,688,437 $3.14 Million
Q3 2022

Nov 14, 2022

BUY
$1.81 - $2.76 $332,538 - $507,075
183,723 New
183,723 $355,000
Q2 2022

Aug 15, 2022

SELL
$1.34 - $5.34 $41,782 - $166,506
-31,181 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$4.58 - $6.8 $132,426 - $196,615
-28,914 Reduced 48.11%
31,181 $143,000
Q4 2021

Feb 14, 2022

SELL
$5.23 - $7.18 $533,052 - $731,799
-101,922 Reduced 62.91%
60,095 $386,000
Q3 2021

Nov 15, 2021

BUY
$5.94 - $8.75 $13,442 - $19,801
2,263 Added 1.42%
162,017 $1 Million
Q2 2021

Aug 16, 2021

SELL
$7.54 - $9.79 $137,989 - $179,166
-18,301 Reduced 10.28%
159,754 $1.28 Million
Q1 2021

May 17, 2021

SELL
$4.76 - $11.25 $68,558 - $162,033
-14,403 Reduced 7.48%
178,055 $1.72 Million
Q3 2020

Nov 16, 2020

BUY
$2.3 - $3.72 $442,653 - $715,943
192,458 New
192,458 $479,000
Q2 2020

Aug 17, 2020

SELL
$1.33 - $3.63 $833,479 - $2.27 Million
-626,676 Closed
0 $0
Q1 2020

May 15, 2020

SELL
$1.27 - $2.33 $532,038 - $976,102
-418,928 Reduced 40.07%
626,676 $902,000
Q4 2019

Feb 14, 2020

BUY
$1.3 - $2.72 $966,451 - $2.02 Million
743,424 Added 246.02%
1,045,604 $2.12 Million
Q3 2019

Nov 14, 2019

BUY
$1.93 - $4.21 $583,207 - $1.27 Million
302,180 New
302,180 $710,000

Others Institutions Holding CMRX

About CHIMERIX INC


  • Ticker CMRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,622,896
  • Market Cap $85M
  • Description
  • Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs i...
More about CMRX
Track This Portfolio

Track Aqr Capital Management LLC Portfolio

Follow Aqr Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aqr Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Aqr Capital Management LLC with notifications on news.